UBS analyst Jeffrey Hung lowered his price target on Concert Pharmaceuticals (NASDAQ: CNCE) to $18.00 (from $28.00) but maintained a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE